News >

Lenalidomide Shows Activity in Low-Risk MDS

Published: Thursday, Dec 22, 2016

Arjan A. van de Loosdrecht, MD, PhD

Arjan A. van de Loosdrecht, MD, PhD

Results from the randomized phase II HOVON89 trial showed that nearly 40% of patients with low intermediate-1 risk myelodysplastic syndrome (MDS) who were refractory to erythropoietin and granulocyte-colony stimulating factor (EPO/G-CSF) experienced hematologic improvement with erythroid response (HI-E) after being treated with lenalidomide (Revlimid) monotherapy. These results were reported at the 2016 American Society of Hematology Annual Meeting in San Diego.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x